LY 456236 hydrochloride

Pricing Availability   Qty
Description: Selective mGlu1 antagonist
Alternative Names: MPMQ hydrochloride
Chemical Name: 6-Methoxy-N-(4-methoxyphenyl)-4-quinazolinamine hydrochloride
Purity: ≥99% (HPLC)
Datasheet
Citations
Reviews (1)
Literature (5)

Biological Activity for LY 456236 hydrochloride

LY 456236 hydrochloride is a selective mGlu1 receptor antagonist (IC50 values are 143 nM and > 10 μM for mGlu1 and mGlu5 receptors respectively). Reduces hyperalgesic behavior induced by formalin in both mouse and rat with ED50 values of 28 and 16.3 mg/kg respectively.

Technical Data for LY 456236 hydrochloride

M. Wt 317.77
Formula C16H15N3O2.HCl
Storage Desiccate at RT
Purity ≥99% (HPLC)
CAS Number 338736-46-2
PubChem ID 9926998
InChI Key AVKFOWUSTVWZQN-UHFFFAOYSA-N
Smiles Cl.COC1=CC=C(NC2=C3C=C(OC)C=CC3=NC=N2)C=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for LY 456236 hydrochloride

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 6.36 20

Preparing Stock Solutions for LY 456236 hydrochloride

The following data is based on the product molecular weight 317.77. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.2 mM 15.73 mL 78.67 mL 157.35 mL
1 mM 3.15 mL 15.73 mL 31.47 mL
2 mM 1.57 mL 7.87 mL 15.73 mL
10 mM 0.31 mL 1.57 mL 3.15 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets for LY 456236 hydrochloride

References for LY 456236 hydrochloride

References are publications that support the biological activity of the product.

Shannon et al (2005) Anticonvulsant effects of LY456236, a selective mGlu1 receptor antagonist. Neuropharmacology 49 188 PMID: 16011839

Bertorelli et al (2005) Selective blockade of metabotropic glutamate subtype mGluR1 receptors induce anti-nociceptive effects. Neuropharmacology 49 231


If you know of a relevant reference for LY 456236 hydrochloride, please let us know.

View Related Products by Product Action

View all Glutamate (Metabotropic) Group I Receptor Antagonists

Keywords: LY 456236 hydrochloride, LY 456236 hydrochloride supplier, Selective, mGlu1, mGluR1, antagonists, mGlur, Group, I, Receptors, Glutamate, Metabotropic, LY456236, hydrochloride, MPMQ, (Metabotropic), 2390, Tocris Bioscience

Citations for LY 456236 hydrochloride

Citations are publications that use Tocris products.

Currently there are no citations for LY 456236 hydrochloride. Do you know of a great paper that uses LY 456236 hydrochloride from Tocris? Please let us know.

Reviews for LY 456236 hydrochloride

Average Rating: 5 (Based on 1 Review.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used LY 456236 hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Action via NMDA receptors.
By Sergiy Sylantyev on 04/02/2021
Assay Type: Ex Vivo
Species: Mouse
Cell Line/Tissue: Hippocampus

1 microM LY 456236 was tested on action potentials generated by current injection into CA3 hippocampal neuron. Application of LY increased significantly a number of action potentials. This effect disappeared after partial block of NMDA receptors. Illustration: control recording of action potentials (top) and recording with LY 456236 (bottom).

Can be easily diluted, no problem with long-time storage in aliquots.

review image

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Metabotropic Glutamate Receptors Scientific Review

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.